Chondrozoumakis Georgios, Chatzimichail Eleftherios, Habra Oussama, Vounotrypidis Efstathios, Papanas Nikolaos, Gatzioufas Zisis, Panos Georgios D
Department of Ophthalmology, University Hospital of Heraklion, 71500 Heraklion, Greece.
Department of Ophthalmology, University Hospital of Basel, 4031 Basel, Switzerland.
J Clin Med. 2025 Feb 18;14(4):1343. doi: 10.3390/jcm14041343.
Diabetic retinopathy (DR) is a leading cause of vision loss globally, with early detection and intervention critical to preventing severe outcomes. This narrative review examines the role of retinal biomarkers-molecular and imaging-in improving early diagnosis, tracking disease progression, and advancing personalized treatment for DR. Key biomarkers, such as inflammatory and metabolic markers, imaging findings from optical coherence tomography and fluorescence angiography and genetic markers, provide insights into disease mechanisms, help predict progression, and monitor responses to treatments, like anti-VEGF and corticosteroids. While challenges in standardization and clinical integration remain, these biomarkers hold promise for a precision medicine approach that could transform DR management through early, individualized care.
糖尿病视网膜病变(DR)是全球视力丧失的主要原因,早期检测和干预对于预防严重后果至关重要。本叙述性综述探讨了视网膜生物标志物(分子和影像学)在改善DR的早期诊断、跟踪疾病进展以及推进个性化治疗方面的作用。关键生物标志物,如炎症和代谢标志物、光学相干断层扫描和荧光血管造影的影像学结果以及基因标志物,有助于深入了解疾病机制、预测疾病进展并监测对抗血管内皮生长因子(anti-VEGF)和皮质类固醇等治疗的反应。尽管在标准化和临床整合方面仍存在挑战,但这些生物标志物有望实现精准医疗,通过早期个体化护理改变DR的管理方式。